Pulse Therapeutics has developed a breakthrough medical device designed to significantly increase the effectiveness of the clot busting drug t-PA for the ER‐based treatment of ischemic stroke. Pulse Therapeutics completed pre ‐clinical animal studies which demonstrated that intravenously-administered biocompatible iron particles, when controlled by a compact external magnet, substantially accelerate blood diffusion. The Company believes that this will allow t-PA to reach the clot more quickly and at higher concentrations, resulting in dramatically faster dissolution of the clot as compared to standard IV t-PA delivery and ultimately faster reperfusion. During 2012, the Company commenced human clinical studies in Australia and was granted 2 patents.